Yuli 2022: On July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing a next-generation chimeric antigen receptor (CAR)-T cell therapy platform targeting solid cancer, announced that they had entered into a strategic partnership MOU concerning the development of a new CAR-T cell therapies. The MOU was in regard to the development of new CAR-T cell therapies. Through the use of this memorandum of understanding (MOU), GenScript ProBio and ACT Therapeutics have come to an agreement to further their collaboration in the field of cell therapy.
ACT Therapeutics da GenScript ProBio suna kan aiwatar da rattaba hannu kan kwangilar haɓakawa da samar da ƙwayoyin cuta na plasmid da ƙwayoyin cuta don bututun farko na ACT Therapeutics' Advanced CAR-T Platform (ACT dandamali), wanda kuma za a ba da izini don samar da albarkatun ƙasa. don ACT Therapeutics' bututun na gaba. Kwangilar za ta ƙunshi samar da plasmids da ƙwayoyin cuta don bututun farko na ACT Therapeutics' Advanced CAR-T Platform.
Sakamakon wannan yarjejeniya, GenScript ProBio an ɗaukaka shi zuwa matsayin abokin tarayya na duniya wanda zai iya tallafawa dandamali na ACT don maganin ACT.
Dandalin ACT wata fasaha ce ta zamani mai zuwa da kuma fasahar jiyya ta kwayoyin halitta wacce ke kai hari kan antigens ta hanyar shigar da kwayoyin halittar da aka tsara don kai hari ga waɗancan antigens cikin ƙwayoyin rigakafi. Ana isar da waɗannan kwayoyin halitta zuwa ƙwayoyin rigakafi ta hanyar amfani da ƙwayoyin cuta. GenScript ProBio yana da ingantaccen tsarin ci gaban ƙwayoyin cuta da kuma dandamalin sabis na tsayawa ɗaya don samar da GMP, duka biyun suna da mahimmanci don haɓakar tantanin halitta da jiyya.
ACT Therapeutics’ ACT platform is an advanced CAR-T technology that has a next-generation structure that goes beyond the second-generation CAR-T cell therapy and targets existing cutar kansa. This is accomplished by overcoming the immune suppression microenvironment of solid cancer and activating the immune cells that are surrounding the cancer. Several studies have also used animals to test the ACT platform to see how well it works and if it is safe. These studies have also confirmed that the platform can be used to treat solid cancer while staying in the immunosuppressive environment of that cancer. Additionally, it complements the shortcomings of the existing second-generation CAR-T, which makes it a competitive technology for the treatment of solid cancer.
ACT Therapeutics is a Korean bio venture company that has received initial investment through DAYLI Partners, Korea’s leading bio and healthcare venture capital, since its establishment in 2020, and has been recognized for its technology such as receiving pre-series A investment in Samho Green Investment. DAYLI Partners is Korea’s leading bio and healthcare venture capital since its establishment in 2020. At the moment, investment consultations are being held with various securities firms and venture capital companies in order to entice Series A investment.
Brian H. Min, CEO of GenScript ProBio, said, “We are very happy to cooperate with ACT therapeutics in strategic partnership, and we are looking forward to support ACT Therapeutics’ ACT platform as a global partner through our accumulated technology.”
Seogkyoung-Kong, Shugaba na ACT Therapeutics, ya ce, "Mun kammala shirye-shiryen dandali na ACT don fitowa a duniya ta hanyar haɗin gwiwa tare da GenScript ProBio. Za mu hanzarta ci gaban jiyya da ke niyya da ƙwararrun cututtukan daji masu ƙarfi.
Game da GenScript ProBio
GenScript ProBio is a subsidiary of GenScript Biotech Corporation, proactively providing end-to-end CDMO service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in cell and gene therapy (CGT), vaccine discovery, biologics discovery and antibody protein drug development to accelerate drug development for customers. GenScript ProBio has established companies in the United States, the Netherlands, South Korea, Shanghai, Hong Kong, Nanjing and other places to serve global customers, and supported customers in the United States, Europe, Asia Pacific and other regions to obtain more than 30 IND approvals.
Game da manufar "Innovation ta hanyar Haɗin kai", GenScript ProBio ya himmatu wajen taimaka wa abokan ciniki su rage lokaci don haɓaka ƙwayoyin ƙwayoyin cuta daga ganowa zuwa tallace-tallace, rage farashin R&D da gina kyakkyawar makoma.
